Aggressive lung cancer with bone metastases and concurrent localized breast cancer

Patient Info: Anonymized, Female | Stage IV

Metastatic Site: Bone: skull, spine, clavicle

The patient was still receiving carboplatin and Taxol for aggressive lung cancer with bone metastases, while her caregiver reported rapid clinical improvement, pain relief, disappearance of a visible forehead metastasis, and 1 cm reduction in a concurrent localized breast tumor.

Delayed adrenal insufficiency after lung cancer immunotherapy

Patient Info: Anonymized, male, 60s | Stage II

Imaging and bronchoscopy in November 2024 showed no lung-cancer recurrence or metastasis. By June 2026, he had not experienced another adrenal crisis while continuing hormone replacement.

PubMed CentralRead more →

A man with lung cancer develops kidney and lung side effects during durvalumab treatment

Patient Info: Anonymized, Male, 60s

Alive at 200 weeks with sustained improvement in proteinuria and kidney injury after durvalumab was discontinued.

PubMed CentralRead more →

More than 5 years living with metastatic lung adenocarcinoma after stepwise molecular testing

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: HER2 amplification, EGFR L858R mutation, PD-L1 <1%

Metastatic Site: brain, lung

As of April 2026, she remained on gefitinib with no active tumor lesions after complete regression of lung metastases, more than 5 years (66 months) after her original diagnosis.

PubMed CentralRead more →

Stage IIIB lung cancer: heart inflammation from durvalumab immunotherapy, mistaken at first for tumor spreading to the heart

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: No actionable driver mutations identified; PD-L1 tumor proportion score <1%

She recovered cardiac function after treatment for durvalumab-associated myocarditis and remained without lung-cancer relapse or cardiac decline for more than 4 years, with no additional anticancer therapy.

PubMed CentralRead more →

Whole-liver radiation for Stage IV small cell lung cancer with diffuse liver metastases

Patient Info: Anonymized, Male, 70+ | Stage IV

Metastatic Site: liver, bone

After renewed liver progression and declining performance status, chemotherapy was stopped and supportive care began. He died in a palliative care unit on July 27, 2019.

PubMed CentralRead more →

Lung adenocarcinoma that spread to the thyroid 9 years later

Patient Info: Anonymized, Female, 60s | Stage IV

Metastatic Site: thyroid

After the thyroid metastasis was removed, she started systemic chemotherapy and remained under oncology management.

PubMed CentralRead more →

HER2-mutated lung cancer: restarting targeted therapy after lung inflammation

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: HER2 exon 20 insertion; PD-L1 negative

Metastatic Site: brain

Trastuzumab deruxtecan was restarted successfully after lung inflammation improved, but it was discontinued after 9 cycles when the cancer progressed.

PubMed CentralRead more →

Stage IV lung cancer presenting with a paraneoplastic neurologic syndrome and mixed tumor features

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: PD-L1 0%

Metastatic Site: bone (T10 and L5 vertebrae)

He died after rapid deterioration with severe encephalopathy, weakness and respiratory distress; advanced metastatic lung cancer with progressive paraneoplastic neurologic involvement was considered the most likely cause.

PubMed CentralRead more →

Stable lung cancer after recovery from a severe immunotherapy complication

Patient Info: Anonymized, Male, 60s

At 8-month follow-up, the primary lung tumor remained radiologically stable on maintenance chemotherapy without evidence of progression.

PubMed CentralRead more →

Stage IVA EGFR-mutant lung adenocarcinoma: clonal evolution, chemoimmunotherapy response, osimertinib rechallenge, and death after progression

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: Markers changed over time: started with EGFR L747S/L858R; later MET-amplified, PD-L1 TPS 80%, high TMB clone; later EGFR reappeared.

Metastatic Site: pleura, peritoneal nodule, retroperitoneal lymph nodes

The patient died on 30 April 2025 after progression through multiple lines and infection related to treatment-associated myelosuppression.

PubMed CentralRead more →

Stage IV EGFR-mutated lung adenocarcinoma: high-dose furmonertinib after CNS progression

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Initial EGFR L858R mutation. Later blood testing showed EGFR p.S553Y variation; CEA rose and fell with treatment.

Metastatic Site: brain/meninges; bilateral pleura/lungs; mediastinal…

As of June-September 2024, the left lung lesion was stable to slightly smaller on escalated furmonertinib, but brain/CNS lesions had progressed and required dose escalation to 240 mg/day; later imaging was declined.

PubMed CentralRead more →

Recurrent squamous lung cancer with tumor emboli, acute limb ischemia, brain metastases, and death

Patient Info: Anonymized, Male, 60s | Stage Metastatic/Advanced

Biomarkers: p40-positive; TTF-1-negative; PD-L1 not expressed / no PD-L1 reported in raw case

Metastatic Site: brain/cerebral metastases; tumor emboli in upper and…

The patient developed recurrent acute limb ischemia from tumor emboli, then new cerebral metastases, and died from advanced disease 7 months after the bilateral lower-limb ischemia presentation.

PubMed CentralRead more →

Small Cell Lung Cancer: Montessa's Survivor Story

Patient Info: Montessa, Female, Under 40

As of June 2026, Montessa was sharing her recovery after limited-stage small cell lung cancer treatment with concurrent chemotherapy and radiation followed by brain radiation.

The Patient StoryRead more →

Stage IV EGFR-mutated lung cancer responds after targeted therapy intolerance

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR L858R mutation; PIK3CA E545K mutation; acquired ROS1 rearrangement

Metastatic Site: pleura|pericardium|bone|lungs

Chemotherapy produced a partial response that remained sustained for 7 months at the latest follow-up.

PubMed CentralRead more →

Stage IIIA small-cell lung cancer with anti-NMDAR encephalitis: initial complete response, recurrence, and death

Patient Info: Anonymized, Male, 60s

Biomarkers: CSF positive for anti-NMDAR antibodies; no tumor molecular biomarkers reported

The patient initially had rapid neurologic recovery and complete radiologic response after carboplatin, etoposide, and atezolizumab, but the primary lung lesion recurred 7 months later and he died 21 months after disease onset.

PubMed CentralRead more →

Stage IV squamous lung cancer with steroid-refractory immune-related gastritis after pembrolizumab

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: Gastric biopsy during immune gastritis showed CD8-positive lymphocyte inflammation, no cancer

After about 2 years of carboplatin, pemetrexed, and pembrolizumab, lung cancer treatment was stopped because of tumor growth; the later immune-related gastritis improved after escalation to infliximab, while the cancer course remained a setback/progression story.

PubMed CentralRead more →

Stage III lung cancer treatment complicated by immune-related lung inflammation

Patient Info: Anonymized, Male, 60s | Stage III

Biomarkers: EGFR-negative; ALK-negative; ROS1-negative

Mediastinal lymph nodes later enlarged despite additional systemic treatment, prompting radiation and further therapy.

PubMed CentralRead more →

Stage IV lung cancer response followed by immune-related lung inflammation

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR-negative; ALK-negative; ROS1-negative

Metastatic Site: pleura

After the lung inflammation improved, he did not resume tumor-directed chemotherapy, immunotherapy, or radiation and remained generally well.

PubMed CentralRead more →

Stage IIIA lung adenocarcinoma: major pathological response after neoadjuvant immunochemotherapy, complicated by DILI/TEN

Patient Info: Anonymized, Male, 50s | Stage III

Biomarkers: No lung molecular biomarkers reported

At 23 months after thoracoscopic left upper lobectomy, he was clinically stable with no evidence of tumor recurrence; severe postoperative DILI/TEN had improved after stopping the offending drug and intensive supportive treatment.

PubMed CentralRead more →

Small-cell lung cancer: envafolimab response complicated by immune-related diabetes, pneumonitis, and later submandibular progression

Patient Info: Anonymized, Male, 60s | Stage Metastatic/Advanced

Biomarkers: ProGRP and NSE were elevated at diagnosis. Tumor molecular biomarkers were not reported; diabetes antibodies were negative.

Metastatic Site: left submandibular region / adjacent lymph nodes

After initial partial response on envafolimab, carboplatin, etoposide, and thoracic radiotherapy, he developed immune-related diabetes, pneumonitis, and progressive left submandibular metastatic disease requiring iodine-125 seeds and later anlotinib.

PubMed CentralRead more →

Stage IV EGFR-positive lung cancer treated for nearly 5 years before progression

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR L858R mutation

Metastatic Site: liver

The cancer later progressed despite chemotherapy, and he died from lung cancer 4 years and 8 months after diagnosis.

PubMed CentralRead more →

Extensive-stage small-cell lung cancer with malignant superior vena cava syndrome

Patient Info: Anonymized, Male, 60s

After superior vena cava stenting, facial and upper-extremity edema improved, he was discharged on hospital day 7, and he lived at home without recurrent SVCS symptoms until death from worsening lung cancer about 2 months later.

PubMed CentralRead more →

Pulmonary epithelioid hemangioendothelioma with complete response after neoadjuvant therapy

Patient Info: Anonymized, Male, 60s

Biomarkers: WWTR1-CAMTA1 fusion; vascular markers supported epithelioid hemangioendothelioma; lung cancer markers were absent.

The patient achieved radiographic disappearance of the lung tumor after neoadjuvant paclitaxel/carboplatin plus bevacizumab. Surgery then showed no residual tumor and lymph nodes were negative; CT follow-up through April 2024 showed no recurrence.

PubMed CentralRead more →